- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Cell Cancer, Squamous, Carcinoma, Squamous Cell
- Interventions
- MEDI0562
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,596
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
- Interventions
- PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
- Biological · Drug
- Lead sponsor
- Katy Peters, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Tumor, Solid
- Interventions
- Durvalumab and Tremelimumab
- Drug
- Lead sponsor
- John L. Villano, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Metastasis
- Interventions
- THOR-707, Checkpoint inhibitor, anti-EGFR antibody
- Drug
- Lead sponsor
- Synthorx, Inc, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Cancer, Immune-related Adverse Event
- Interventions
- Medical chart review
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Smoking
- Interventions
- Integrated Care, Cognitive-Behavioral Treatment for Insomnia, Desensitization Treatment for Insomnia
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Metastatic Melanoma, Skin Cancer
- Interventions
- cyclophosphamide, fludarabine phosphate, Aldesleukin, ALVAC gp100 Vaccine, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Melanoma
- Interventions
- Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
- Procedure · Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Interventions
- Bempegaldesleukin, Nivolumab
- Biological
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 765 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 62
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
- Interventions
- Not listed
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
- Interventions
- Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 80
- States / cities
- Phoenix, Arizona • La Jolla, California • Madera, California + 60 more
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Interventions
- CAN-2409, Valacyclovir, Temozolomide, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Nivolumab, oral decitabine, Tetrahydrouridine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Cleveland, Ohio
- Conditions
- Melanoma
- Interventions
- Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Solid Tumors
- Interventions
- BAY2416964, Pembrolizumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2050
- U.S. locations
- 8
- States / cities
- College Station, Texas • Dallas, Texas • Fort Worth, Texas + 5 more
- Conditions
- Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
- Interventions
- Cyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- San Diego, California • San Francisco, California • Tampa, Florida + 5 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 838
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- TG4050
- Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Tumor Lysate Vaccine, Imiquimod, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostate Cancer Metastatic
- Interventions
- HB-302/HB-301 Alternating 2-Vector Therapy
- Biological
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • San Marcos, California • Miami, Florida + 5 more
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- Nivolumab, Surgical Resection, Radiation (5 days), Radiation (3 days)
- Drug · Procedure · Radiation
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon